Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Cash & Current Investments for 7 consecutive years, with $592.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 2.73% to $592.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was $592.9 million, a 2.73% decrease, with the full-year FY2025 number at $592.9 million, down 2.73% from a year prior.
  • Cash & Current Investments was $592.9 million for Q4 2025 at Nurix Therapeutics, up from $428.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $609.6 million in Q4 2024 to a low of $244.0 million in Q1 2024.
  • A 5-year average of $372.4 million and a median of $326.5 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: fell 24.86% in 2023, then surged 125.29% in 2025.
  • Nurix Therapeutics' Cash & Current Investments stood at $295.7 million in 2021, then grew by 4.54% to $309.1 million in 2022, then dropped by 6.87% to $287.9 million in 2023, then surged by 111.73% to $609.6 million in 2024, then decreased by 2.73% to $592.9 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Cash & Current Investments are $592.9 million (Q4 2025), $428.8 million (Q3 2025), and $485.8 million (Q2 2025).